Raptor Pharmaceutical Corp. (NASDAQ:RPTP) issued its quarterly earnings data on Thursday. The company reported ($0.30) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.30), Analyst Ratings.Net reports.
On the ratings front, analysts at Oppenheimer reiterated a “positive” rating on shares of Raptor Pharmaceutical Corp. in a research note to investors on Wednesday, June 26th.
Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $10.50.
Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded up 3.35% during mid-day trading on Thursday, hitting $10.50. Raptor Pharmaceutical Corp. has a 52 week low of $4.35 and a 52 week high of $10.85. The stock’s 50-day moving average is currently $9.78. The company’s market cap is $582.0 million.
Raptor Pharmaceuticals Corp. (NASDAQ:RPTP), formerly TorreyPines Therapeutics, Inc, is an early development-stage Company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.